Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials

Dyne Therapeutics, Inc.

DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.
DYNE-251 in DELIVER trial: 0.88% mean dystrophin expression at 5 mg/kg at 6 months, exceeding eteplirsen with 24-fold lower dose.
Favorable safety profiles: no related serious adverse events; dose escalation to 6.8 mg/kg (ACHIEVE) and 40 mg/kg (DELIVER) supported.
Company plans to initiate registrational cohorts for both programs by end of 2024, with next data updates in second half of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.